Treatment Details – 8.8 months
|Patients: This Phase II trial involved 41 patients with malignant pleural mesothelioma.|
Treatment: The treatment consisted of a chemotherapy drug, oral etoposide (VP 16-213, vepesid).
Toxicity: Grade 3-4 toxicities included hematological, nausea/vomiting, cutaneous reaction, and alopecia.
Results: Median survival was 38 weeks (8.8 months).